Trifiletti R R, Snyder S H
Mol Pharmacol. 1984 Nov;26(3):458-69.
The interactions of zopiclone and suriclone, representatives of nonbenzodiazepine cyclopyrrolone anxiolytics, with central-type benzodiazepine receptors have been characterized in rat and bovine brain. While zopiclone potently (IC50 approximately 50 nM) inhibits [3H]Ro-15-1788 binding in an apparent mass action fashion, suriclone and its metabolite 35,489 RP are extremely potent (IC50 approximately 350 pM and 1 nM, respectively) and display Hill coefficients of approximately 2.0. Like classical benzodiazepines, none of the cyclopyrrolones studied display selectivity for type I or type II benzodiazepine receptors. Using [3H]suriclone, saturable high affinity sites for cyclopyrrolone anxiolytics were directly labeled in rat and bovine brain. The regional distribution and pharmacologic specificity of [3H]suriclone and [3H]Ro-15-1788 binding sites are similar, suggesting that [3H]suriclone recognition sites reside on the benzodiazepine receptor complex. Unlike classical benzodiazepine agonists, such as diazepam, the binding of [3H]suriclone is not modulated by GABA, Cl-, pentobartibal, or tracazolate. Unlike those of [3H]diazepam, [3H]suriclone-binding sites are only minimally affected by photoaffinity labeling with flunitrazepam. Whereas the binding affinities of [3H]Ro-15-1788, [3H]flunitrazepam, and [3H]ethyl beta-carboline 3-carboxylate increase at lower temperatures, [3H]suriclone binds with higher affinity at higher temperatures. Scatchard analysis of [3H]flunitrazepam, [3H]ethyl beta-carboline 3-carboxylate, and [3H]Ro-15-1788 binding in the presence of all cyclopyrrolones studied reveals an apparent noncompetitive pattern of inhibition of binding in each case; by contrast, inhibition of [3H]suriclone binding by Ro-15-1788 flunitrazepam, methyl beta-carboline 3-carboxylate and all of the cyclopyrrolones studied appears competitive. The dissociation kinetics of [3H]Ro-15-1788 indicate that cyclopyrrolones, but not benzodiazepines, increase the dissociation rate of [3H]Ro-15-1788 from its membrane receptors; the converse is true for [3H]suriclone dissociation kinetics. The association kinetics of [3H]suriclone suggest that suriclone induces a conformational change upon binding to receptors. Taken together, these results indicate that [3H]suriclone labels a site on the benzodiazepine receptor complex allosteric to the recognition site for benzodiazepines. A model is proposed to describe the interaction between benzodiazepines and cyclopyrrolones.
非苯二氮䓬类环吡咯酮类抗焦虑药佐匹克隆和舒立克隆与中枢型苯二氮䓬受体的相互作用已在大鼠和牛脑中得到表征。佐匹克隆以明显的质量作用方式强力抑制(IC50约为50 nM)[3H]Ro-15-1788结合,而舒立克隆及其代谢物35,489 RP则极其强力(IC50分别约为350 pM和1 nM),且希尔系数约为2.0。与经典苯二氮䓬类药物一样,所研究的环吡咯酮类药物均未表现出对I型或II型苯二氮䓬受体的选择性。使用[3H]舒立克隆,在大鼠和牛脑中直接标记了环吡咯酮类抗焦虑药的可饱和高亲和力位点。[3H]舒立克隆和[3H]Ro-15-1788结合位点的区域分布和药理特异性相似,表明[3H]舒立克隆识别位点位于苯二氮䓬受体复合物上。与经典苯二氮䓬类激动剂(如地西泮)不同,[3H]舒立克隆的结合不受GABA、Cl-、戊巴比妥或曲卡唑酯的调节。与[3H]地西泮不同,[3H]舒立克隆结合位点仅受到氟硝西泮光亲和标记的轻微影响。虽然[3H]Ro-15-1788、[3H]氟硝西泮和[3H]β-咔啉-3-羧酸乙酯在较低温度下结合亲和力增加,但[3H]舒立克隆在较高温度下结合亲和力更高。在所有所研究的环吡咯酮类药物存在的情况下,对[3H]氟硝西泮、[3H]β-咔啉-3-羧酸乙酯和[3H]Ro-15-1788结合进行的Scatchard分析显示,每种情况下结合抑制均呈现明显的非竞争性模式;相比之下,Ro-15-1788、氟硝西泮、β-咔啉-3-羧酸甲酯以及所研究的所有环吡咯酮类药物对[3H]舒立克隆结合的抑制似乎具有竞争性。[3H]Ro-15-1788的解离动力学表明,环吡咯酮类药物而非苯二氮䓬类药物会增加[3H]Ro-15-1788从其膜受体的解离速率;对于[3H]舒立克隆解离动力学则相反。[3H]舒立克隆的结合动力学表明,舒立克隆在与受体结合时会诱导构象变化。综上所述,这些结果表明[3H]舒立克隆标记了苯二氮䓬受体复合物上一个与苯二氮䓬识别位点呈变构关系的位点。提出了一个模型来描述苯二氮䓬类药物与环吡咯酮类药物之间的相互作用。